Related Experiment Videos
[New aspects in clinical cardiology: sex-based differences in cardiovascular morbidity and mortality]
Insights
Heart failure incidence declined in women but not men. Digoxin therapy may increase women's mortality risk, but this requires further investigation due to study limitations.
Area of Science:
- Cardiology
- Clinical Pharmacology
- Epidemiology
Context:
- Heart disease progression and outcomes can differ between sexes.
- Historical data show declining heart failure incidence in women, unlike men.
- Factors like sodium excretion and obesity disproportionately affect women's cardiovascular mortality risk.
Purpose:
- To investigate potential sex-based differences in heart disease incidence and survival.
- To assess the effect of digoxin therapy on mortality risk in women.
- To critically evaluate existing studies on sex-based differences in cardiovascular disease treatment and outcomes.
Summary:
- A post-hoc analysis of the DIG study suggested increased mortality risk for women on digoxin, but this conclusion is limited by a narrow focus on gender without considering other significant patient differences.
- Conflicting data exist regarding sex-based differences in cardiovascular disease, highlighting the need for comprehensive analyses.
- The Women's Health Initiative trial unequivocally demonstrated that combined estrogen/progestin therapy should not be used for primary prevention of coronary heart disease in postmenopausal women due to increased cardiovascular risks.
Impact:
- Highlights the critical need for sex-specific considerations in cardiovascular research and clinical practice.
- Underscores the limitations of subgroup analyses that do not account for multifactorial patient characteristics.
- Provides evidence-based guidance against using hormone replacement therapy for primary cardiovascular prevention in postmenopausal women.
Abstract:
No relevant sex-based differences in hemodynamic parameters have been described until now but the course of any heart disease may be modified by factors that act differently in men and women. In a study comparing the incidence of heart disease and patient survival over the past 50 years, the incidence of heart failure was found to have declined in women but not in men. With increased sodium excretion and obesity, the hazard ratios for cardiovascular mortality were higher in women. A post-hoc subgroup analysis of the DIG study was conducted to assess potential sex-based differences in the effect of digoxin. The authors conclude that digoxin therapy is associated with an increased risk of death in women (P = 0.34). The comparison of the effects of digoxin was limited simply to gender only and no other subgroup analyses were preformed although the characteristics of the patients show significant differences in more than 20 parameters. Hence, the conclusion of these authors can hardly be accepted. Contrary to these partly conflicting data, the primary results from the Women's Health Initiative randomized controlled trial focused on defining the risks and benefits of hormone replacement in postmenopausal women give an unambiguous answer: combined estrogen/progestin therapy should not be initiated or continued for the primary prevention of coronary heart disease, furthermore, it increases the risks of cardiovascular disease, breast cancer, venous thromboembolism and biliary tract surgery.